Westlake Village-based MannKind Corporation is receiving some extra help to advance some of its short and long-term growth strategies. Announced Aug. 6, MannKind, a biotech company focused on inhaled ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good morning, and welcome to the MannKind Corporation Second ...

Good morning, and welcome to the MannKind Corporation Second Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded on August 6, 2025, and will be available for ...

MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

The biopharmaceutical company posted adjusted earnings of $0.05 per share for the second quarter, matching analyst estimates. However, revenue came in at $76.53 million, below the consensus estimate ...

The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said ...

MannKind Corporation (MNKD) said on Wednesday that it has entered into up to $500 million strategic financing agreement with ...

Strengthens MannKind’s capital structure with flexible, long-term, non-dilutive fundingMannKind to receive $75 million in cash at closing DANBURY, Conn. and WESTLAKE VILLAGE, Calif. and NEW YORK, Aug.

Conference call today at 9:00 am ET2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD ...

Analysts anticipate MannKind to report an earnings per share (EPS) of $0.06. The announcement from MannKind is eagerly ...

MannKind Corp (NASDAQ:MNKD) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate for Q2 2025 revenue ...

MannKind Corporation (NASDAQ: MNKD) is one of the best strong buy penny stocks to buy now. In a report released on July 29, ...